23andMe Bankruptcy: What Happens to Your Genetic Data?
Ask about Knowledge at Wharton
Episode Description
ABOUT THE EPISODE In this episode, Dan Loney speaks with Gideon Nave, Associate Professor of Marketing at the Wharton School, about the ethical and legal implications of genetic data privacy in the wake of 23andMe’s bankruptcy. Nave explores the unique sensitivity of genetic information, the risks of data misuse, informed consent, and the role of regulation. He also shares his personal perspective as both a researcher and former customer of 23andMe.
ABOUT THE PODCAST The Wharton Business Daily podcast features interviews with top business leaders, innovators, and renowned Wharton faculty about the latest news, fascinating trends, and issues impacting both consumers and the business world. Episodes are recorded at the Wharton School.
#DataPrivacy #TechEthics #DigitalPrivacy #PersonalData ----- The Wharton School of the University of Pennsylvania is committed to sharing its intellectual capital through Knowledge at Wharton, the school’s online business analysis journal.
Launched in 1999, Knowledge at Wharton offers free access to:
- Articles, podcasts, and videos highlighting Wharton faculty research and analysis of current business trends - Interviews with book authors from Wharton School Press - In-depth series of curated content like Wharton Executive Education’s Nano Tools for Leaders - A searchable database of more than 10,000 articles covering all aspects of business - A weekly newsletter that delivers Knowledge at Wharton insights directly to your inbox
Visit the Knowledge at Wharton homepage: https://whr.tn/3qUpSBE Subscribe to the Knowledge at Wharton YouTube channel: https://whr.tn/3DEAgAU
Read the full transcriptHide the full transcript
- Dan Loney: Well, the bankruptcy case of genetic testing site 23andMe is bringing forward an interesting case around personal data to
- dive deeper into. What should people do who have provided personal data to one company but see it gets sold to another?
- Gideon Nave is Associate Professor of Marketing here at the Wharton School, and he joins us right now. Gideon, great to
- talk to you again. How are you, sir? Gideon Nave: I'm well. Always great to talk to you too. - I would guess
- that when you have instances like this, that for the most part, people don't necessarily even think about the data. It's
- just kind of part of doing business here. - Yeah, I mean, we do know that our data is everywhere and
- moving around between entities, sometimes without very clear understanding of us and transparency of this process.
- But I think genetic data is something a bit more special than just what we buy and what we like on Facebook.
- - What makes this so important in your mind? - There are several layers here, but I'd say the number one layer
- is that our genetic data is something that we cannot change about ourselves. We are born with it. You can measure it for
- us even before we are born, and it continues to follow us throughout our lives. So you know, I may be able to change my
- behavior, but I will not be able to change my genetics. And my genetics includes information for many other things that,
- because they are determined by genetics. Even to some degree, I mean, many things are just partly determined by genetics,
- like personality and so on. But even these things, the genetic component of it, I will not be able to change about myself, and
- this data includes information about it. Not to mention that lots of these things are things that I even don't know about
- myself, that maybe are in the data and I'm not aware of it. Maybe I will even choose to not know deliberately. I will not
- want to know about it. That's just the first layer. I mean, I can continue with many other layers.
- - So the concern would probably be, if a company were to acquire the data that maybe is not necessarily in that field, but
- is looking to maximize potential profitability of that data. - Yeah, I mean, let's say it this way. You
- know, they say it in the Silicon Valley, that if you're not paying for the product, you are the product. We kind of agreed to
- the fact that we are customers. And as a result of being customers, we are providing something, which is our data, to
- the companies, which makes them live and survive. But again, this is a bit different for the case of genetic data. We
- actually paid companies like 23andMe to give us a service, to genotype us. And the sad thing about this company is that, once
- they gave us the service, we don't have a strong reason to continue being a customer, right? So it's not like their
- genetic data now keeps giving us a lot of value once we got the genetic report. Again, unless there are some progresses in
- genetic research, and then they can give us some additional insight, which they did and actually didn't work so well.
- Part of the reason that it doesn't work well is that genetics, you know, in most cases, it's informative of
- things, but it's not deterministic. It gives you some probabilistic knowledge that, with the current level of
- genetic data, is relatively small. We actually never gave 23andMe our data. Just, "Hey, go do research with our data, or go
- advertise with our data." But they have this data and they can use it. The question is whether we are now in a kind of a
- unilateral situation where we don't get benefit from our data given to them, and they can still benefit from our data. And
- this is a bit, I guess, an issue related to autonomy and to informed consent of like, you know, do I want this to be
- done? If the answer is yes, then, you know, many people did give informed consent to 23andMe to use the data for research,
- and I think that this is great. If you're not okay with this, then you can ask 23andMe to delete your data. You're
- legally allowed to do this. Maybe we want to thank the European Union for giving us this right to be forgotten. And
- you can ask every company, whether it's Facebook or 23andMe, to forget about you. And if you're not fine with it, go do
- it. - But how do we avoid the misuse of this personal data, this genetic data? And
- I guess, from a regulatory landscape, you mentioned about what Europe has done around this topic. Obviously, we don't have
- the same kind of structure here in the United States, but it becomes a more important topic as we move forward since our
- lives are so much more digital than they were a couple of decades ago. - It's an extremely important topic, and it goes beyond genetics. But
- I think genetics has several components that make it especially alarming, like genetic data is considered very
- sensitive also within medicine. How do we deal with it? Well, you know, I think first of all, many of the GDPR regulations are
- very much adopted by American companies because they also serve European customers. I think that one potential
- limitation of the regulations is the thing that, you know, with consent, you're allowed -- the companies can do everything they
- want. And we are consenting to numerous things every day. Like, every time we are going to a new website, we are consenting to
- stuff. We have become so automatically consenting to everything that it's very clear that nothing is going to stop us
- probably from consenting to many other things we don't want. And then, you know, we have to go back, and there is a lot of
- effort of thinking of, what did I consent to, and where will I -- it's an issue. It's a problem. I mean, there may be a business
- opportunity here for companies that will kind of try to look at what did you consent to, and try to figure out where your data
- is. - One of the things that I saw noted in looking at what we might see play out with the 23andMe bankruptcy process is also,
- whoever that company is who comes in and maybe acquires it, is having a level of transparency so that the
- customers of 23andMe truly understand where this data is going to be potentially living and going down the
- road. - Absolutely. And I think that as a society, we have a very strong interest that this data will be collected.
- 23andMe is a company that is very important for the future of medicine. It's a company that collected data, that
- facilitated breakthrough discoveries of research. Even, you know, you can say genetics maybe has not delivered
- as much as we hoped for when the Human Genome Project concluded, and we thought that we were going to solve all of our
- problems. But we do gain a lot, and it's actually crucial that we have very large samples when it comes to genetic data. So we
- actually all, as a society, are kind of in a place where it's good for us that everyone give their genetic data, but you
- know, we do have to pay a price for it. We do know also that there are data breaches. There are a lot of potential downsides
- here, and this is like a classical place where you need regulation. I think that in a place like this, where the
- benefit is of society, but the data is so, so, so sensitive, I think regulation must take place. And at the moment, we
- don't have much of it. We have regulation about using genetic data for insurance, for job applications, and so on. We
- don't have it for many other things. And so once this is the case, it's a bit of a broken area where we have to depend on
- maybe the GDPR, which is related to many types of data. We rely on the consent, we rely on the companies not
- actually just unilaterally modifying the agreements that they have with us and doing stuff with the data. Yeah, there
- is a lot of -- there are a lot of problems here. I personally can tell you that I did -- I was a customer of 23andMe
- and I told them that, "I want my data. I will have my data. But I don't want them to keep my data, because at the
- moment, I don't feel like I have control of where it's going to go." And it's a bit sad, because I'm using data of many, many
- people in my own research where we are -- where I'm using it to identify genetic variations that are related to all sorts of
- human conditions, which I find very important. - Gideon, great to talk to you again. Thanks very much for your time today. - Thank
- you. - Thank you. Gideon Nave, Associate Professor of Marketing here at the Wharton School.
Brief Summary
Gideon Nave discusses 23andMe's bankruptcy, genetic data privacy, and the need for better regulations on personal data ownership.
Key points
- The Importance of Genetic Data. Gideon Nave explains why genetic data is unique and sensitive, emphasizing its lifelong impact.
- Consent and Data Ownership. The conversation highlights the complexities of consent regarding personal data and its implications.
- Regulation of Genetic Data. Gideon Nave stresses the need for regulation in handling sensitive genetic data.
Episode highlights
- The Importance of Genetic DataGideon Nave explains why genetic data is unique and sensitive, emphasizing its lifelong impact.“Our genetic data is something that we cannot change about ourselves.”1:06May 23, 2025
- Consent and Data OwnershipThe conversation highlights the complexities of consent regarding personal data and its implications.“We are consenting to numerous things every day.”5:44May 23, 2025
- Regulation of Genetic DataGideon Nave stresses the need for regulation in handling sensitive genetic data.“Regulation must take place for sensitive data.”7:52May 23, 2025




